title: An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
authors.affiliation: Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri 63017, USA. satish.singh@pfizer.com
authors.forename: Satish K
authors.initials: SK
authors.lastname: Singh
authors.forename: Nataliya
authors.initials: N
authors.lastname: Afonina
authors.forename: Michel
authors.initials: M
authors.lastname: Awwad
authors.forename: Karoline
authors.initials: K
authors.lastname: Bechtold-Peters
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: Blue
authors.forename: Danny
authors.initials: D
authors.lastname: Chou
authors.forename: Mary
authors.initials: M
authors.lastname: Cromwell
authors.forename: Hans-Juergen
authors.initials: HJ
authors.lastname: Krause
authors.forename: Hanns-Christian
authors.initials: HC
authors.lastname: Mahler
authors.forename: Brian K
authors.initials: BK
authors.lastname: Meyer
authors.forename: Linda
authors.initials: L
authors.lastname: Narhi
authors.forename: Doug P
authors.initials: DP
authors.lastname: Nesta
authors.forename: Thomas
authors.initials: T
authors.lastname: Spitznagel
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D004345:Drug Industry / Q000592:standards*; D006801:Humans; D053758:Nanoparticles; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000592:standards*; D011506:Proteins / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use*; D018570:Risk Assessment
chemical_list: D004364:Pharmaceutical Preparations; D011506:Proteins